AGWCA
XBI icon

Annis Gardner Whiting Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-446
Closed -$57K – 1267
2026
Q1 		$57K Sell
446
-46
-9% -$5.74K 0.01% 555
2025
Q4 		$60K Buy
+492
New +$56.4K 0.01% 495

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's XBI Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 446 shares — an estimated $57K sold.

Annis Gardner Whiting Capital Advisors first reported a position in XBI in Q4 2025 and held it in 2 quarters. The position peaked at $60K in Q4 2025. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 446 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $57K.
  • Annis Gardner Whiting Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $60K in Q4 2025.
  • 932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.